NCT01892384View on ClinicalTrials.gov

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 28, 2013

Primary Completion Date

December 5, 2013

Study Completion Date

December 5, 2013

Conditions
Schizophrenia
Interventions
DRUG

Placebo

matching placebo

DRUG

BI 409306

BI 409306

Trial Locations (1)

Unknown

1289.18.1 Boehringer Ingelheim Investigational Site, Austin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY